Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection
Open Access
- 7 July 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (7) , e0157546
Abstract
Enumeration of CD4+ T lymphocytes is important for pre-ART disease staging and screening for opportunistic infections, however access to CD4 testing in resource limited settings is poor. Point of care (POC) technologies can facilitate improved access to CD4 testing. We evaluated the analytical performance of a novel POC device the FACSPresto compared to the FACSCalibur as a reference standard and to the PIMA, a POC device in widespread use in sub-Saharan Africa. Specimens were obtained from 253 HIV infected adults. Venous blood samples were analyzed on the FACSPresto and the FACSCalibur, in a subset of 41 samples additional analysis was done on the PIMA. The absolute CD4 count results obtained on the FACSPresto were comparable to those on the FACSCalibur with low absolute (9.5cells/μl) and relative bias (3.2%). Bias in CD4% values was also low (1.06%) with a relative bias of 4.9%. The sensitivity was lower at a CD4 count threshold of ≤350cells/μl compared with ≤500cells/μl (84.9% vs. 92.8%) resulting in a high upward misclassification rate at low CD4 counts. Specificity at thresholds of ≤350cells/μl and ≤500cells/μl were 96.6% and 96.8% respectively. The PIMA had a high absolute (-68.6cells/μl) and relative bias (-10.5%) when compared with the FACSCalibur. At thresholds of ≤350cells/μl and ≤500cells/μl the sensitivity was 100% and 95.5% respectively; specificity was 85.7% and 84.2% respectively. The coefficients of repeatability were 4.13%, 5.29% and 9.8% respectively. The analytic performance of the FACSPresto against the reference standard was very good with better agreement and precision than the PIMA. The FACSPresto had comparable sensitivity at a threshold of 500 cells/μl and better specificity than the PIMA. However the FACSPresto showed reduced sensitivity at low CD4 count thresholds. The FACSPresto can be reliably used as a POC device for enumerating absolute CD4 count and CD4% values.Keywords
Funding Information
- Becton Dickenson Biosciences
- National Institute of Allergy and Infectious Diseases (1K08AI104348)
This publication has 31 references indexed in Scilit:
- Evaluation of PIMA™® Point of Care Technology for CD4 T Cell Enumeration in KenyaPLOS ONE, 2013
- Performance of the PointCare NOW System for CD4 Counting in HIV Patients Based on Five Independent EvaluationsPLOS ONE, 2012
- Evaluation of Portable Point-of-Care CD4 Counter with High Sensitivity for Detecting Patients Eligible for Antiretroviral TherapyPLOS ONE, 2012
- Loss to Follow-Up of Adults in Public HIV Care Systems in Central Mozambique: Identifying Obstacles to TreatmentJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South AfricaClinical Infectious Diseases, 2009
- Early Antiretroviral Therapy and Mortality among HIV-Infected InfantsNew England Journal of Medicine, 2008
- Affordable CD4 T-cell enumeration for resource-limited regions: A status report for 2008Cytometry Part B: Clinical Cytometry, 2008
- Multiple method comparison: Statistical model using percentage similarityCytometry Part B: Clinical Cytometry, 2003
- The Prognostic Value of Cellular and Serologic Markers in Infection with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986